IN2007DE04250A - - Google Patents

Info

Publication number
IN2007DE04250A
IN2007DE04250A IN4250DE2007A IN2007DE04250A IN 2007DE04250 A IN2007DE04250 A IN 2007DE04250A IN 4250DE2007 A IN4250DE2007 A IN 4250DE2007A IN 2007DE04250 A IN2007DE04250 A IN 2007DE04250A
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Dina Blasberger
Boris Pertsikov
Boris Tishin
Ben Zion Dolitzki
Lev M Yudovich
Marina Yu Etinger
Gennady A Nisnevich
Michael Yuzefovich
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IN2007DE04250A publication Critical patent/IN2007DE04250A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
IN4250DE2007 2001-11-14 2007-06-05 IN2007DE04250A (en:Method)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33280201P 2001-11-14 2001-11-14
US34227301P 2001-12-21 2001-12-21

Publications (1)

Publication Number Publication Date
IN2007DE04250A true IN2007DE04250A (en:Method) 2007-08-31

Family

ID=26988392

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4250DE2007 IN2007DE04250A (en:Method) 2001-11-14 2007-06-05

Country Status (14)

Country Link
US (2) US6849737B2 (en:Method)
EP (1) EP1465894A4 (en:Method)
JP (1) JP2005508993A (en:Method)
KR (2) KR20050044449A (en:Method)
CN (1) CN1307177C (en:Method)
CA (2) CA2465928C (en:Method)
HR (1) HRP20040511A2 (en:Method)
IL (1) IL161969A0 (en:Method)
IN (1) IN2007DE04250A (en:Method)
IS (1) IS7260A (en:Method)
MX (1) MX242714B (en:Method)
NO (1) NO20042433L (en:Method)
PL (1) PL371732A1 (en:Method)
WO (1) WO2003041647A2 (en:Method)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04002192A (es) * 2001-09-07 2005-02-17 Teva Pharma Formas cristalinas de clorhidrato de valaciclovir.
US20040197396A1 (en) * 2001-11-05 2004-10-07 Fain Helen S Anhydrous crystal form of valaciclovir hydrochloride
MX242714B (es) * 2001-11-14 2006-12-15 Teva Pharma Sintesis y purificacion de valaciclovir.
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
EP1551838B1 (en) * 2002-10-16 2006-08-09 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
AU2003289995A1 (en) * 2002-12-09 2004-06-30 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
WO2004106338A1 (en) * 2003-05-30 2004-12-09 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
EP2014660A3 (en) * 2003-06-02 2009-07-15 Teva Pharmaceutical Industries Ltd Novel crystalline forms of valacyclovir hydrochloride
EP1706406A1 (en) * 2004-01-21 2006-10-04 Teva Pharmaceutical Industries Ltd. Process for the preparation of valacyclovir hydrochloride
CA2572268A1 (en) * 2004-06-30 2006-02-02 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
CN101068814A (zh) * 2004-09-04 2007-11-07 特瓦制药工业有限公司 分离的伐昔洛韦杂质，制备伐昔洛韦杂质的方法及其作为参比标准物的应用
US7958087B2 (en) * 2004-11-17 2011-06-07 Iron Mountain Incorporated Systems and methods for cross-system digital asset tag propagation
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
GB0605344D0 (en) * 2006-03-17 2006-04-26 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
JP5152180B2 (ja) * 2007-04-27 2013-02-27 味の素株式会社 バラシクロビルの製造方法
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
US10836765B2 (en) * 2016-03-03 2020-11-17 Aurobindo Pharma Ltd Process for the preparation of valacyclovir
CN106632335A (zh) * 2016-12-27 2017-05-10 河南康达制药有限公司 一种盐酸伐昔洛韦的制备方法
CN114621227B (zh) * 2022-02-28 2024-07-09 海南久常制药有限公司 一种盐酸伐昔洛韦、制剂及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
GB8719367D0 (en) 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
DE69426880T2 (de) * 1993-06-10 2001-10-31 Rolabo S.L., Zaragoza Verfahren zur herstellung von aminosäureester von nukleosid analogen
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
US6117453A (en) * 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
US5672243A (en) * 1995-11-28 1997-09-30 Mosel Vitelic, Inc. Antireflection coating for highly reflective photolithographic layers comprising chromium oxide or chromium suboxide
PT874631E (pt) * 1996-01-19 2004-04-30 Glaxo Group Ltd Utilizacao de valaciclovir para a manufactura de um medicamento para o tratamento de herpes genital por aplicacao diaria unica
US6040446A (en) 1996-01-26 2000-03-21 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
US5756736A (en) * 1996-01-26 1998-05-26 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
JP2001503767A (ja) * 1996-11-12 2001-03-21 メディヴィル・アクチボラグ ヌクレオシド
MXPA04002192A (es) * 2001-09-07 2005-02-17 Teva Pharma Formas cristalinas de clorhidrato de valaciclovir.
US20040197396A1 (en) * 2001-11-05 2004-10-07 Fain Helen S Anhydrous crystal form of valaciclovir hydrochloride
MX242714B (es) * 2001-11-14 2006-12-15 Teva Pharma Sintesis y purificacion de valaciclovir.
AU2003240213A1 (en) * 2002-06-24 2004-01-06 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
EP1551838B1 (en) * 2002-10-16 2006-08-09 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
AU2003289995A1 (en) * 2002-12-09 2004-06-30 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
WO2004106338A1 (en) * 2003-05-30 2004-12-09 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
EP2014660A3 (en) * 2003-06-02 2009-07-15 Teva Pharmaceutical Industries Ltd Novel crystalline forms of valacyclovir hydrochloride
EP1706406A1 (en) * 2004-01-21 2006-10-04 Teva Pharmaceutical Industries Ltd. Process for the preparation of valacyclovir hydrochloride
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof

Also Published As

Publication number Publication date
EP1465894A4 (en) 2008-10-08
WO2003041647A2 (en) 2003-05-22
KR20070020149A (ko) 2007-02-16
JP2005508993A (ja) 2005-04-07
NO20042433L (no) 2004-07-22
CA2465928A1 (en) 2003-05-22
EP1465894A2 (en) 2004-10-13
MX242714B (es) 2006-12-15
CN1307177C (zh) 2007-03-28
HRP20040511A2 (en) 2004-10-31
KR20050044449A (ko) 2005-05-12
CA2465928C (en) 2010-01-19
MXPA04004656A (es) 2004-08-13
IL161969A0 (en) 2005-11-20
IS7260A (is) 2004-05-11
US20030153757A1 (en) 2003-08-14
PL371732A1 (en) 2005-06-27
CN1612878A (zh) 2005-05-04
CA2649826A1 (en) 2003-05-22
US20050130993A1 (en) 2005-06-16
US6849737B2 (en) 2005-02-01
WO2003041647A3 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
BE2022C531I2 (en:Method)
BE2022C502I2 (en:Method)
BE2017C057I2 (en:Method)
BE2015C046I2 (en:Method)
AU2002307149A8 (en:Method)
JP2002110544A5 (en:Method)
JP2002151276A5 (en:Method)
BRPI0209186B1 (en:Method)
BRPI0204884A2 (en:Method)
IN2007DE04250A (en:Method)
JP2002231419A5 (en:Method)
IN2006MU00429A (en:Method)
BRPI0101486B8 (en:Method)
JP2002049203A5 (en:Method)
HU0203358D0 (en:Method)
BRPI0210463A2 (en:Method)
JP2002235437A5 (en:Method)
JP2002245342A5 (en:Method)
AU2000280389A8 (en:Method)
HU0202042D0 (en:Method)
JP2002229718A5 (en:Method)
JP2002165075A5 (en:Method)
JP2002215019A5 (en:Method)
JP2002224239A5 (en:Method)
JP2002011894A5 (en:Method)